HYPAQUE-M,90%
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Nov 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYPAQUE-M, 90% is an injectable contrast medium approved in 1955 for diagnostic imaging procedures. As a legacy radiographic contrast agent, it is used to enhance visualization of internal structures during medical imaging. The drug functions as an iodinated contrast agent that increases radiodensity in target tissues.
LOE Approaching
Product is approaching loss of exclusivity with low competitive pressure (30%), indicating potential team restructuring or strategic repositioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on HYPAQUE-M offers limited career growth due to mature lifecycle and approaching LOE. Roles focus on defensive commercial strategies, margin optimization, and legacy portfolio management rather than innovation or market expansion.
Brand ManagerSales Representative
Worked on HYPAQUE-M,90% at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.